Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing a two-pronged strategy to tackle major neurological disorders, focusing on multiple sclerosis (MS) and the acute effects of alcohol intoxication. The company's pipeline includes Lucid-MS, a patented new chemical entity for MS, and unbuzzd, a dietary supplement designed to support alcohol metabolism and reduce hangover symptoms.
Multiple sclerosis affects an estimated 2.9 million people globally, with about one million in the United States. The disease commonly strikes young adults between ages 20 and 50, with a mean age of 32, and is twice as prevalent in women. Existing therapies often fall short, leaving patients with limited options. Lucid-MS takes a fundamentally different approach, aiming to address the underlying mechanisms of MS rather than just managing symptoms. The company is currently supporting phase 2 development of Lucid-MS through an ongoing imaging collaboration with Massachusetts General Hospital, which could provide critical insights into the drug's efficacy.
In addition to MS, Quantum BioPharma has developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. This product targets a widespread issue, as alcohol misuse contributes to numerous health and safety problems. By offering a natural supplement that helps the body process alcohol more efficiently, unbuzzd could reduce the immediate negative impacts of alcohol consumption.
The company's focus on these two areas highlights a commitment to addressing significant neurological unmet needs. For more information on Quantum BioPharma and its pipeline, visit the company's newsroom at https://ibn.fm/QNTM. Investors should review the full terms of use and disclaimers available at http://IBN.fm/Disclaimer.
Forward-looking statements in this article involve risks and uncertainties that could cause actual results to differ materially. These include factors beyond management's control, as detailed in the company's filings with the SEC. No undue reliance should be placed on these forward-looking statements, and the company undertakes no duty to update them unless required by law.
